Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending March 29, 2010. The report discloses a notifiable share interest transaction involving JCR Pharmaceuticals Co., Limited.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to a specific acquisition transaction:
- Acquisition Cost: Approximately £29.2 million.
- Shares Acquired: 3,076,923 Common shares of JCR Pharmaceuticals Co., Limited.
Material Changes
On March 26, 2010, GSK entered into an agreement with Mitsui Principal Investments to acquire additional shares of JCR. This transaction resulted in the following material changes to GSK's holdings:
- Ownership Stake: Increased from 16.73% to approximately 25% of outstanding Common shares.
- Voting Rights: GSK's total holding now represents approximately 25% of the total voting rights in JCR.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, or a discussion of risks and contingencies beyond the disclosure of the share acquisition. The transaction details were previously disclosed to the Press Club of the Tokyo Stock Exchange on March 29, 2010.
Key Facts for Investor Verification
- Verify the total cost of the JCR acquisition (£29.2 million) and the resulting 25% ownership stake.
- Confirm the date of the agreement (March 26, 2010) and the completion of the transaction.
- Review the separate announcement issued to the Tokyo Stock Exchange for additional transaction details not included in this Form 6-K.
- Note that this filing does not contain GSK's consolidated financial results for the period.